1. Effusanin E suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-κB and COX-2 signaling.
- Author
-
Zhuang M, Zhao M, Qiu H, Shi D, Wang J, Tian Y, Lin L, and Deng W
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Apoptosis drug effects, Carcinoma drug therapy, Carcinoma metabolism, Carcinoma pathology, Caspase 3 metabolism, Caspase 9 metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cyclooxygenase 2 genetics, Diterpenes chemistry, Diterpenes therapeutic use, Humans, Isodon chemistry, Isodon metabolism, Male, Mice, Mice, Nude, Nasopharyngeal Neoplasms drug therapy, Nasopharyngeal Neoplasms metabolism, Nasopharyngeal Neoplasms pathology, Poly(ADP-ribose) Polymerases metabolism, Antineoplastic Agents pharmacology, Cyclooxygenase 2 metabolism, Diterpenes pharmacology, NF-kappa B metabolism, Signal Transduction drug effects
- Abstract
Rabdosia serra is well known for its antibacterial, anti-inflammatory and antitumor activities, but no information has been available for the active compounds derived from this plant in inhibiting human nasopharyngeal carcinoma (NPC) cell growth. In this study, we isolated and purified a natural diterpenoid from Rabdosia serra and identified its chemical structure as effusanin E and elucidated its underlying mechanism of action in inhibiting NPC cell growth. Effusanin E significantly inhibited cell proliferation and induced apoptosis in NPC cells. Effusanin E also induced the cleavage of PARP, caspase-3 and -9 proteins and inhibited the nuclear translocation of p65 NF-κB proteins. Moreover, effusanin E abrogated the binding of NF-κB to the COX-2 promoter, thereby inhibiting the expression and promoter activity of COX-2. Pretreatment with a COX-2 or NF-κB-selective inhibitor (celecoxib or ammonium pyrrolidinedithiocarbamate) had an additive effect on the effusanin E-mediated inhibition of proliferation, while pretreatment with an activator of NF-κB/COX-2 (lipopolysaccharides) abrogated the effusanin E-mediated inhibition of proliferation. Effusanin E also significantly suppressed tumor growth in a xenograft mouse model without obvious toxicity, furthermore, the expression of p50 NF-κB and COX-2 were down-regulated in the tumors of nude mice. These data suggest that effusanin E suppresses p50/p65 proteins to down-regulate COX-2 expression, thereby inhibiting NPC cell growth. Our findings provide new insights into exploring effusanin E as a potential therapeutic compound for the treatment of human nasopharyngeal carcinoma.
- Published
- 2014
- Full Text
- View/download PDF